Study #2022-0282
A Phase 1/2 Study Of BIO-106 As Monotherapy Or In Combination With Pembrolizumab In Patients With Advanced Cancers (STARBRIDGE-1)
MD Anderson Study Status
Not Accepting
Treatment Agent
BIO-106, Pembrolizumab
Description
A first-in-human study using BIO-106 as a single agent and in combination with pembrolizumab in advanced cancers.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Advanced Cancer, Advanced Solid Tumor, Cancer, Oncology
Study phase:
Physician name:
Funda Meric-Bernstam
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-855-479-2433
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.